It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's also beneficial because the HIV virus is always evolving.
MedPage Today on MSN
Single-Tablet Combo Matched Complex Regimens in Older HIV Patients
"Time has stood still" for many who've been on complex regimens for decades ...
A large international clinical trial has unveiled a promising new option for people living with highly treatment-resistant HIV.
Single-pill treatment proves as effective at suppressing virus as multi-pill therapy, while long-acting preventive injections ...
Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to a manageable lifetime condition for those who are successfully being treated.Initially, ...
Data from two studies presented at the Conference on Retroviruses and Opportunistic Infections support the use of a novel, ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at ...
In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...
In a global phase 3 trial, a single-tablet combination of bictegravir and lenacapavir effectively suppressed HIV in people ...
Women who used a dolutegravir-based regimen had less mother-to-infant transmission of HIV compared with those on efavirenz-based regimens. Approximately 2.58 million children aged 0 to 19 years around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results